Intelligent Bio Solutions Reports 46% Revenue Growth but Faces Net Loss and Liquidity Concerns

Intelligent Bio Solutions Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company achieved revenues of $1,060,802 for the three months ended March 31, 2026, marking a 46% increase from $728,867 in the same period the previous year. For the nine months ending March 31, 2026, total revenue reached $3,069,373, up 39% from $2,208,648 in the prior year. The increase in revenue was attributed to the addition of 33 new customers and a higher reorder rate for consumables. Despite the revenue growth, the company reported a net loss of $2,862,712 for the quarter, compared to a loss of $2,543,526 in the same quarter of 2025.

The company’s total assets increased to $14,862,792 as of March 31, 2026, from $8,249,786 as of June 30, 2025. This growth was primarily driven by a substantial increase in cash and cash equivalents, which rose to $6,862,204 from $1,019,909. However, total liabilities also increased, reaching $6,111,476, up from $5,435,962, largely due to higher accounts payable and accrued expenses. The company’s shareholders’ equity improved significantly to $8,751,316, compared to $2,813,824 in the previous fiscal period.

Operationally, Intelligent Bio Solutions has made strides in expanding its market presence and product offerings. The company launched its Intelligent Fingerprinting Drug Screening System, which is now commercially available in select international markets. Additionally, the company has entered into strategic partnerships, including a collaboration with Bouygues UK for deploying its drug screening technology across multiple project sites. The company also reported a successful shipment of drug screening readers manufactured under a new partnership with Syrma Johari MedTech Ltd., enhancing its production capacity.

Despite these advancements, the company faces challenges, including rising operating expenses, which increased to $3,648,177 for the three months ended March 31, 2026, compared to $3,074,968 in the prior year. This rise was driven by increased selling, general, and administrative expenses, as well as higher development and regulatory approval costs. The company anticipates continued operating losses and has expressed concerns regarding its liquidity, indicating that its current cash reserves may not be sufficient to fund operations for the next 12 months without additional financing.

Looking ahead, Intelligent Bio Solutions aims to expand its market share in the UK and Europe, enhance its product capabilities, and pursue regulatory approvals in the U.S. The company is actively seeking additional funding through equity or debt financing to support its growth initiatives and address its liquidity needs. However, management has acknowledged the uncertainty surrounding the availability of such funding, which could impact the company's operational plans and long-term viability.